Share on StockTwits

Citigroup Inc. initiated coverage on shares of Ampio Pharmaceuticals (NASDAQ:AMPE) in a research note issued on Thursday, reports. The firm set a “buy” rating and a $21.00 price target on the stock. Citigroup Inc.’s price objective points to a potential upside of 198.30% from the company’s current price.

Separately, analysts at Aegis raised their price target on shares of Ampio Pharmaceuticals from $15.00 to $16.00 in a research note on Monday, March 17th. They now have a “buy” rating on the stock.

Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) traded up 8.31% on Thursday, hitting $7.04. 1,601,683 shares of the company’s stock traded hands. Ampio Pharmaceuticals has a 1-year low of $4.31 and a 1-year high of $10.86. The stock’s 50-day moving average is $5.94 and its 200-day moving average is $7.49. The company’s market cap is $296.6 million.

Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.